Cargando…

The colorectal cancer immune paradox revisited

Tumor infiltrating lymphocytes (TILs) represent a strong independent predictor of relapse and overall survival in colorectal cancer (CRC). However, it appears that a majority of CRCs, i.e., microsatellite stable (MSS) tumors, are refractory to immune checkpoint blockers. The results of recent compre...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelova, Mihaela, Charoentong, Pornpimol, Hackl, Hubert, Trajanoski, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801462/
https://www.ncbi.nlm.nih.gov/pubmed/27057454
http://dx.doi.org/10.1080/2162402X.2015.1078058
_version_ 1782422583692492800
author Angelova, Mihaela
Charoentong, Pornpimol
Hackl, Hubert
Trajanoski, Z.
author_facet Angelova, Mihaela
Charoentong, Pornpimol
Hackl, Hubert
Trajanoski, Z.
author_sort Angelova, Mihaela
collection PubMed
description Tumor infiltrating lymphocytes (TILs) represent a strong independent predictor of relapse and overall survival in colorectal cancer (CRC). However, it appears that a majority of CRCs, i.e., microsatellite stable (MSS) tumors, are refractory to immune checkpoint blockers. The results of recent comprehensive analyses of genomic data provide possible answers.
format Online
Article
Text
id pubmed-4801462
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-48014622016-04-07 The colorectal cancer immune paradox revisited Angelova, Mihaela Charoentong, Pornpimol Hackl, Hubert Trajanoski, Z. Oncoimmunology Author's View Tumor infiltrating lymphocytes (TILs) represent a strong independent predictor of relapse and overall survival in colorectal cancer (CRC). However, it appears that a majority of CRCs, i.e., microsatellite stable (MSS) tumors, are refractory to immune checkpoint blockers. The results of recent comprehensive analyses of genomic data provide possible answers. Taylor & Francis 2015-08-27 /pmc/articles/PMC4801462/ /pubmed/27057454 http://dx.doi.org/10.1080/2162402X.2015.1078058 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Angelova, Mihaela
Charoentong, Pornpimol
Hackl, Hubert
Trajanoski, Z.
The colorectal cancer immune paradox revisited
title The colorectal cancer immune paradox revisited
title_full The colorectal cancer immune paradox revisited
title_fullStr The colorectal cancer immune paradox revisited
title_full_unstemmed The colorectal cancer immune paradox revisited
title_short The colorectal cancer immune paradox revisited
title_sort colorectal cancer immune paradox revisited
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801462/
https://www.ncbi.nlm.nih.gov/pubmed/27057454
http://dx.doi.org/10.1080/2162402X.2015.1078058
work_keys_str_mv AT angelovamihaela thecolorectalcancerimmuneparadoxrevisited
AT charoentongpornpimol thecolorectalcancerimmuneparadoxrevisited
AT hacklhubert thecolorectalcancerimmuneparadoxrevisited
AT trajanoskiz thecolorectalcancerimmuneparadoxrevisited
AT angelovamihaela colorectalcancerimmuneparadoxrevisited
AT charoentongpornpimol colorectalcancerimmuneparadoxrevisited
AT hacklhubert colorectalcancerimmuneparadoxrevisited
AT trajanoskiz colorectalcancerimmuneparadoxrevisited